{"id":45548,"date":"2022-06-27T18:01:46","date_gmt":"2022-06-27T16:01:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/2022-drug-discovery-outsourcing-market-size-share-trends-analysis-report-researchandmarkets-com\/"},"modified":"2022-06-27T18:01:46","modified_gmt":"2022-06-27T16:01:46","slug":"2022-drug-discovery-outsourcing-market-size-share-trends-analysis-report-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/2022-drug-discovery-outsourcing-market-size-share-trends-analysis-report-researchandmarkets-com\/","title":{"rendered":"2022 Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report by Drug Type (Small, Large Molecules), by Therapeutic Area (Respiratory System, Immunomodulation), by Workflow, and Segment Forecasts, 2022-2030”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe global drug discovery outsourcing market size is expected to reach USD 6.3 billion by 2030 at a CAGR of 7.4%\n<\/p>\n

\nThe COVID-19 pandemic has brought pharmaceutical companies in limelight. Drug discovery is a costly and lengthy process. This has urged pharmaceutical and biotech companies to opt for outsourcing their research activities to academic and private Contract Research Organizations (CROs).\n<\/p>\n

\nRising partnerships between public or private entities accelerate drug discovery processes, which, in turn, increase the global demand for outsourcing services for drug discovery.\n<\/p>\n

\nThis scenario is expected to sustain post the covid implications as well. A rise in cases of chronic diseases has urged companies to develop medicines that extend life expectancy. According to the United Nations, people aged 65 years between 2015 and 2020 are expected to live an additional 17 years.\n<\/p>\n

\nSome of the key therapeutic areas where companies are actively involved in outsourcing include oncology, cardiovascular, and anti-infectives. In November 2020, AstraZeneca collaborated with 9 of the foremost oncology medical centers to expedite research in some of the hardest-to-treat cancers. The company will be funding clinical and non-clinical research proposals from members of this network.\n<\/p>\n

\nThe COVID-19 pandemic has demonstrated the value of drug discovery and development. People across the world are waiting for a vaccine while several companies are proactively involved in developing an effective vaccine to combat COVID-19.\n<\/p>\n

\nPfizer Inc. and BioNTech SE received first approval for the vaccine following a worldwide Phase 3 trial of a potential strain to combat the virus. As for clinical trials, many of them are halted, while some are functional by adopting remote monitoring technologies.\n<\/p>\n

\nThus, the pandemic has brought the pharmaceutical industry to center stage with drug discovery outsourcing becoming a key aspect to develop effective treatments against the virus. This is expected to boost the market revenue for the next 2 years i.e. a short-term boom, after which it shall regain its original growth curve.\n<\/p>\n

\nDrug Discovery Outsourcing Market Report Highlights<\/strong>\n<\/p>\n